Cipla wants Ugandan firm to make its AIDS drug; WHO approves site
This article was originally published in Scrip
The World Health Organization's prequalification programme says the facilities of Ugandan firm Quality Chemical Industries Ltd (QCIL) comply with its good manufacturing practice (GMP) requirements, after Indian generics firm Cipla requested the inspection, as part of a variation application, as it hopes to manufacture one of its pre-qualified antiretrovirals there.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.